David Nichols

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.

Orthobond Corp. develops chemicals to help facilitate better material surface bonding. It offers a technology based on self-assembled monolayers of phosphonate (SAMP) and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company was founded by Gregory E. Lutz and Jeffery Schwartz in 2004 and is headquartered in North Brunswick, NJ.